Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lost genome segments associate with trait diversity during rice domestication.
Zheng X, Zhong L, Pang H, Wen S, Li F, Lou D, Ge J, Fan W, Wang T, Han Z, Qiao W, Pan X, Zhu Y, Wang J, Tang C, Wang X, Zhang J, Xu Z, Kim SR, Kohli A, Ye G, Olsen KM, Fang W, Yang Q. Zheng X, et al. Among authors: fang w. BMC Biol. 2023 Feb 1;21(1):20. doi: 10.1186/s12915-023-01512-6. BMC Biol. 2023. PMID: 36726089 Free PMC article.
Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.
Zhang Z, Xue J, Yang Y, Fang W, Huang Y, Zhao S, Luo F, Cao J, Zeng K, Ma W, Zhan J, Lu F, Zhang L, Zhao H. Zhang Z, et al. Among authors: fang w. MedComm (2020). 2024 Jun 2;5(6):e586. doi: 10.1002/mco2.586. eCollection 2024 Jun. MedComm (2020). 2024. PMID: 38832214 Free PMC article.
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study.
Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, Fang W, Guo Y, Han Y, Yang K, Li Y, Yang J, Fu Z, Chen G, Chen L, Zhou N, Zhou T, Zhang Y, Zhou H, Liu Q, Zhu Y, Zhu H, Xiao S, Zhang L, Zhao H. Ma Y, et al. Among authors: fang w. Lancet Oncol. 2024 May 29:S1470-2045(24)00159-1. doi: 10.1016/S1470-2045(24)00159-1. Online ahead of print. Lancet Oncol. 2024. PMID: 38823410
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.
HARMONi-A Study Investigators; Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K, Song Q, Du X, Sun Y, Li W, Xu F, Wang Z, Yang K, Fan Y, Liu B, Zhao H, Hu Y, Jia L, Xu S, Yi T, Lv D, Lan H, Li M, Liang W, Wang Y, Yang H, Jia Y, Chen Y, Lu J, Feng J, Liu C, Zhou M, Zhou J, Liu X, Zhou N, He M, Dong X, Chen H, Chen Y, Su H, Li X, Zhang Z, Yang L, Cheng Y, Chen L, Hou X, Zhang Y, Guo J, Wang Z, Lu H, Wu D, Feng W, Li W, Huang J, Wang Y, Song X, Peng J, Liu L, Guo Y, Li W, Lu D, Hu M, Wang ZM, Li B, Xia M, Zhang L. HARMONi-A Study Investigators, et al. Among authors: fang w. JAMA. 2024 May 31. doi: 10.1001/jama.2024.10613. Online ahead of print. JAMA. 2024. PMID: 38820549
6,365 results